US EditionRoute 92 Medical’s Neurovascular Interventions Portfolio Approved in Australia - Endovascular Today
Summary by Endovascular Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Route 92 Medical’s Neurovascular Interventions Portfolio Approved in Australia - Endovascular Today
April 1, 2025—Route 92 Medical, Inc. announced approval from the Australian Therapeutic Goods Administration (TGA) for its neurovascular intervention portfolio, which includes its 0.088-inch super-bore reperfusion systems: the FreeClimb 88 catheter powered by Tenzing technology and the Monopoint-based HiPoint 88 super-bore catheter. The company introduced its technology at the Australian and New Zealand Society of Neuroradiology annual scientifi…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
